TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC) – updated interim analysis (IA).

Johann S. de Bono,Niven Mehra,Celestia S. Higano,Fred Saad,Consuelo Buttigliero,Inge M. van Oort,Marielena Mata,Hsiang-Chun Chen,Cynthia G. Healy,M. Luisa Paccagnella,Akos Czibere,Karim Fizazi

TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC) – updated interim analysis (IA).

2020

Johann S. de Bono
Niven Mehra
Celestia S. Higano
Fred Saad
Consuelo Buttigliero
Inge M. van Oort
Marielena Mata
Hsiang-Chun Chen
Cynthia G. Healy
M. Luisa Paccagnella
Akos Czibere
Karim Fizazi

5566Background: PARP inhibitors (PARPi) show antitumor activity in mCRPC/DDRm pts treated with novel hormonal therapy (NHT). TALAPRO-1 is an open-label study evaluating TALA (potent PARP inhibitor/...

Keywords:

Talazoparib
Oncology
DNA Damage Repair
in patient
Interim analysis
castration resistant
Phases of clinical research
Prostate cancer
Pathology
Internal medicine
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations